This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-21 and is reviewed periodically as new material appears.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
sonication Also ultrasonication. The process of irradiating a substance with sound energy, usually at ultrasound (>20 kHz) frequencies, in order to agitate the particles in a sample for various purposes, such as increasing the rate of a chemical reaction or preparing vesicles in mixtures of surfactants and water.
=== Caps-2-PIDDosome === Another important interaction is between Caspase-2 enzyme and PIDD1 to form Caps-2-PIDDosome. The formation of the Caspase–2–PIDDosome relies on the interaction with the adaptor protein RAIDD, which is characterized by the presence of a death domain (DD) and a caspase recruitment domain (CARD). RAIDD and PIDD-CC engage through their death domains (DD) to form a high molecular weight complex. Additionally, the N-terminal caspase recruitment domain (CARD) in RAIDD acts as a docking site for the zymogen of CASP2. This interaction is specifically associated with PIDD-CC, which is derived from the human PIDD1 transcript variant 1, since a small deletion in transcript variant 3 is likely sufficient to prevent RAIDD binding. The presence of PIDD-C in the nucleus is vital for the activation of NF-κB; however, PIDD-CC has also been detected in the nucleolus, an organelle that serves various functions, including ribosome biogenesis and DNA repair.
== Gas separation discovery and development == At Innsbruck, Cremer researched the hydrogenation of acetylene and found difficulty separating two gases with similar adsorption heats using the common methods of the day. She was aware of the liquid absorption chromatography research going on at Innsbruck, so she thought of a parallel method to separate gases which used an inert carrier gas as the mobile phase. She developed mathematical relationships and equations and instrumentation for the first gas chromatograph. Separate components were detected by a thermal conductivity detector. She initially submitted a short academic paper in 1944 to Naturwissenschaften, which was accepted and she informed them that future experimental work would follow. The paper however was not published at the time, because the journal's printing press was destroyed during air bombardment. It was finally published thirty years later in 1976 at which point it was considered a historical document. In December 1944, the university's facilities were badly damaged in an air bombardment and after the war, Cremer, as a German citizen, was not allowed to use the limited facilities. Fritz Prior was one of her postwar students and a high school chemistry teacher. He chose her idea of the gas chromatograph for his dissertation. Until facilities at the University of Innsbruck were usable again, he used his high school's laboratory to continue Cremer's research with her.
Sources: en.wikipedia.org
Research has been ongoing over the past two decades to determine whether copper is a causative or a preventive agent of Alzheimer's disease. For example, as a possible causative agent or an expression of a metal homeostasis disturbance, studies indicate that copper may play a role in increasing the growth of protein clumps in Alzheimer's disease brains, possibly by damaging a molecule that removes the toxic buildup of amyloid beta (Aβ) in the brain. There is an association between a diet rich in copper and iron together with saturated fat and Alzheimer's disease. On the other hand, studies also demonstrate potential beneficial roles of copper in treating rather than causing Alzheimer's disease. For example, copper has been shown to 1) promote the non-amyloidogenic processing of amyloid beta precursor protein (APP), thereby lowering amyloid beta (Aβ) production in cell culture systems 2) increase lifetime and decrease soluble amyloid production in APP transgenic mice, and 3) lower Aβ levels in cerebral spinal fluid in Alzheimer's disease patients. Furthermore, long-term copper treatment (oral intake of 8 mg copper (Cu-(II)-orotate-dihydrate)) was excluded as a risk factor for Alzheimer's disease in a noted clinical trial on humans and a potentially beneficial role of copper in Alzheimer's disease has been demonstrated on cerebral spinal fluid levels of Aβ42, a toxic peptide and biomarker of the disease. More research is needed to understand metal homeostasis disturbances in Alzheimer's disease patients and how to address these disturbances therapeutically.
=== Rich Boyd lawsuit (2006) === In 2006, a lawsuit exposed a possible family disagreement over the chain's corporate leadership. Richard Boyd, one of In-N-Out's vice presidents and co-trustee of two-thirds of the company stock, accused Lynsi Snyder (then known as Lynsi Martinez) and allied corporate executives of trying to force out Esther Snyder and attempting to fire Boyd unreasonably. Pre-empting the suit, Martinez, Snyder, and Taylor appeared in a December video message to employees, telling them not to believe everything they hear. The company then responded with a lawsuit of its own, alleging Boyd had construction work done on his personal property and charged it to the company, as well as favoring contractors with uncompetitive bids. Boyd was then suspended from his role as co-trustee and Northern Trust Bank of California took his place (as co-trustee) until a hearing set for May 10, 2006. However, in April, the judge dismissed two of In-N-Out's claims against Boyd. A trial date of October 17, 2006, was set but never occurred, and a settlement was reached out of court. Ultimately, Boyd was permanently removed from his role as an employee and co-trustee.
Laminin G domain: all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5), cadherin EGF LAG seven-pass G-type receptors (CELSR1, CELSR2, CELSR3), contactin-associated proteins (CNTNAP1, CNTNAP2, CNTNAP3, CNTNAP3B, CNTNAP4, CNTNAP5), some collagens (COL5A1, COL5A3, COL9A1, COL11A1, COL11A2, COL12A1, COL14A1, COL15A1, COL16A1, COL18A1, COL19A1, COL20A1, COL21A1, COL22A1, COL24A1, COL27A1), crumbs homologs 1 and 2 (CRB1, CRB2), fat homologs (FAT1, FAT2, FAT3, FAT4), NEL-like proteins (NELL1, NELL2), neurexins (NRXN1, NRXN2, NRXN3), slit homologs (SLIT1, SLIT2, SLIT3), thrombospondins (THBS1, THBS2, THBS3, THBS4, TSPEAR), agrin (AGRIN), chondroitin sulfate proteoglycan 4 (CSPG4), eyes shut homolog (EYS), growth arrest-specific protein 6 (GAS6), perlecan (HSPG2), pikachurin (EGFLAM), protein S (PROS1), sex hormone-binding globulin (SHBG) and usherin (USH2A) Laminin N-terminal (domain VI): most laminin chains (LAMA1, LAMA2, LAMA3, LAMA5, LAMB1, LAMB2, LAMB3, LAMB4, LAMC1, LAMC3), most netrins (NTN1, NTN3, NTN4, NTNG1, NTNG2), and usherin (USH2A)
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.